GSK news

GSK delivers Q1 EPS of 26.3p before major restructuring and increased dividend of 14p

GSK has today announced that alli – the first clinically proven over the counter weight loss aid – is available in pharmacies across Europe.

GlaxoSmithKline plc (GSK) and Stiefel Laboratories Inc. today announced that they have signed an agreement to create a new world-leading specialist dermatology business.

GlaxoSmithKline plc (GSK) and Pfizer Inc (PFE) today announced they have entered into an agreement to create a new world-leading HIV company focused solely on research, development and commercialisation of HIV medicines.

GlaxoSmithKline (GSK) today announced the submission of two simultaneous regulatory applications to expand the use of Tyverb®/Tykerb® (lapatinib). If authorised, lapatinib could be used as a first-line therapy regimen combined with anti-hormonal therapy for patients with hormone-sensitive, metastatic (or advanced) breast cancer in Europe and the United States.

GlaxoSmithKline (GSK) today received European Commission authorisation for Synflorix™, a paediatric pneumococcal vaccine to protect against life-threatening diseases such as meningitis and bacteraemic pneumonia, as well as middle ear infections.

In its Corporate Responsibility Report published today, GSK reiterated its commitment to running its business responsibly and transparently.

GlaxoSmithKline submits final study data to FDA for cervical cancer vaccine

GlaxoSmithKline plc (the “Group”) announces today that it has sold 5,749,157 shares of common stock, par value of $0.01 per share (the “Shares”), of Quest Diagnostics Inc. (“Quest”).

GSK reiterates commitment to 12 week free access programme